1Sharma P,Sinha M,Shukla R,et al. A randomized con-trolled clinical trial to compare the safety and efficacy of edar-avone in acute ischemic stroke. Ann Indian Acad Neurol,2011,14(2) : 103-106.
2Naritomi H,Moriwaki H,Metoki N,et al. Effects of edara-vone on muscle atrophy and locomotors function in patientswith ischemic stroke : a randomized controlled pilot study.Drugs R D,2010,10(3) : 155-163.
4Shinohara Y,Saito I, Kobayashi S,et al . Edaravone ( radi-cal scavenger) versus sodium ozagrel ( antiplatelet agent ) inacute noncardioembolic ischemic stroke ( EDO trial ) . Cere-brovasc Dis,2009, 27(5) : 485-492.
5Inatomi Y , Takita T , Yonehara T , et al. Efficacy of edara-vone in cardioembolic stroke. Intern Med,2006,45(5):253-257.
6Mishina M,Komaba Y,Kobayashi S,et al. Efficacy ofedaravone,a free radical scavenger,for the treatment of acutelacunar infarction. Neurol Med Chir ( Tokyo ),2005 , 45(7): 344-348.
7Ohta Y , Takamatsu K , Fukushima T,et al. Efficacy of thefree radical scavenger,edaravone,for motor palsy of acute la-cunar infarction. Intern Med , 2009 , 48(8) : 593 -596.
8Nakase T , Yoshioka S,Suzuki A. Free radical scavenger ,edaravone , reduces the lesion size of lacunar infarction in hu-man brain ischemic stroke. BMC Neurol,2011,11(1):39.
9Sinha MK,Anuradha HK,Juyal R , et al. Edaravone in a-cute ischemic stroke,an Indian experience . Neurol Asia,2009,14( 1 ) : 7-10.
10Unno Y,Katayama M,Shimizu H. Does functional outcomein acute ischaemic stroke patients correlate with the amount offree - radical scavenger treatment . a retrospective study of edar-avone therapy. Clin Drug Investig, 2010, 30(3): 143-155.
4Sumer M, Ozdemir I, Eurturk O, et al. Porgression in acute ischemic stroke: frequency, risk factors and prognosis [J]. J Clin Neurosci, 2003,10(2) : 177-180.
5Mauriello A, Sangiorgi G, Palmieri G, al. Hyperfibrinogenemia is associatcd with specific histocytologieal composition and complications of atherosclerotic carotid plaques in patients affected by trsms~ent ischemic attacks. Circulation, 2000, 101: 714-750.
6Munoz Torrero J J, Mora F J, Dtez-Tejedor E. Specific treatment of the acute cerebral infarct. Present and fulture. Rev Neurol, 2000, 31 : 959-982.
7Sherman D G. Antithromhotic therapy in the acute phase: new approaches. Cerebrovasc Dis, 2001,11 Suppl 1 : 49-54.
8Izumi Y, Tsuda Y, lchihara S, el al. Effecls of defibrmadon on hemorhcology, cerebral blood flow velocity, and CO2 reactivity during hypocapnia in normal subjects. S, roke, 1996, 27:1:528-1332.
9Lees K R. Thrombolysis. Br Med Bull, 2000.56:389-400.
10MaybergMR, Furlan A. Ancrod is snake venom an antidote for stroke? JAMA, 2000, 283: 2440-2442.
6Ly den P, Lu M, Jackson C, et al. Underlying structure of the National Institutes of Health Stroke scale: results of a factor analysis. Stroke, 1999, 30(11): 2347-2354.
7Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke, 1999, 30(8): 1538-1541.
8Pandey A, Saxena K, Verma M, et al. Correlative study between neuron-specific enolase and blood sugar level in ischemic stroke patients. J Neurosci Rural Pract, 2011, 2(1): 50-54.
9Bugnicourt JM, Chillon JM, Tribouilloy C, et al. Relation between intracranial artery calcifications and aortic atherosclerosis in ischemic stroke patients. J Neurol, 2010, 257(8): 1338-1343.
10Elgebaly MM, Ogbi S, Li W, et al. Neurovascular injury in acute hyperglycemia and Diabetes: A comparative analysis in experimental stroke. Transl Stroke Res, 2011, 2(3): 391-398.
